Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Cristina Lopez Escola


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


C. Lopez Escola, O. Sheikh, H. Franks, K. Mengoli, S. Karim, S. Khan, A. Arora, I. Hennig

Author affiliations

  • Oncology Department, Nottingham University Hospitals NHS Trust-City Hospital Campus, NG5 1PB - Nottingham/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 851


The Royal Marsden Hospital (RMH) and Gustave Roussy Institute (GRIm) have prospectively validated prognostic scores to aide patient selection for phase I immunotherapy trials in many tumour sites, including NSCLC. These include number of metastatic sites, LDH, Albumin and Neutrophil-to-Lymphocyte Ratio (NLR). GRIm score stratified 155 patients to high-risk and low-risk categories, according to LDH, Albumin and NLR, with median OS of 4 months in high-risk cohort and 17 months in low-risk group. NSCLC was the predominant tumour site in this analysis including 30 stage IV patients. This score had similar design to RMH score, except for number of metastatic sites instead of NLR.


165 consecutive Nottinghamshire patients with stage IIIB/IV NSCLC on PD1/PDL1 immune-checkpoint inhibitors from December 2015 to December 2018 have been retrospectively analysed. At data cut-off in April 2019, 148 - 151 patients were censored for median TTF, PFS and OS, according to GRIm - RMH scores respectively: 17 patients were unclassified into GRIm (10.3%) and 14, into RMH (8.5%) for LDH unavailability; 70 patients remain alive (42.4%), 31 of whom still receiving immunotherapy (18.8%).




mTTF (cycles)mPFS (months)mOS (months)
GRIm score0-1 80 patients (95% CI) Pembrolizumab-61 p Atezolizumab-13 p Nivolumab-3 p9 (9-13) 9 (7.5-11) 7 (4.6-10.5) 67 (6.9-10) 7 (7.5-11) 6 (3.6-7.3) 310 (10-13.5) 11 (11-15) 7.5 (5.2-9.1) 6
2-3 68 patients (95% CI) Pembrolizumab-59 p Atezolizumab-6 p Nivolumab-3 p3 (3.8-7) 3 (4-7.5) 3.5 (0.3-8.1) 12 (3-5.7) 2 (3-6.1) 3 (0.04 - 5.4) 14 (5.1-8.6) 5 (5-9.1) 6 (1.3-10) 1
RMH score0-1 93 patients (95% CI) Pembrolizumab-78 p Atezolizumab-12 p Nivolumab-3 p9 (8.6-12.4) 8 (8.8-13.2) 11 (4.7-12.1) 67 (6.9-9.9) 6.5 (7.2-10.7) 7 (3.3-8) 310 (10-13.5) 11 (10.6-14.6) 8 (5.5-9.5) 6
2-3 58 patients (95% CI) Pembrolizumab-46 p Atezolizumab-9 p Nivolumab-3 p2.5 (3.4-7) 3 (3.7-8.1) 2 (1.35-4.2) 12 (2.6-5.4) 2.5 (2.8-6.2) 3 (0.9-3.4) 13 (4.5-7.9) 4 (4.8-9) 3 (1.7-7.3) 1


GRIm / RMH scores on our population have consistently shown predictive and prognostic relevance, with more favourable TTF, PFS and OS in low-risk groups across any immunotherapy. On treatment stratification, Atezolizumab outcomes show better correlation with RMH score and Nivolumab remains underrepresented at our centre. Our results are consistent with international multi-institutional studies at Gustave Roussy (France) on Lung Immune Prognostic Index (LIPI) and Princess Alexandra Hospital (Australia) on modified LIPI. Disease control has been observed when immune-related adverse events have occurred, suggesting baseline autoimmune antibodies may be predictive of response and immune-related toxicity, a currently open line of observational prospective research.

Clinical trial identification

Not applicable

Editorial acknowledgement

No editorial assistance in the writing of the abstract to be declared

Legal entity responsible for the study

Nottingham University Hospitals NHS Trust at UK.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.